Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × cemiplimab × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 44 Lung Neoplasms 10 Neoplasms 6 Melanoma 5 Head and Neck Neoplasms 4 Neoplasm Metastasis 3 Colorectal Neoplasms 3 Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Ovarian Neoplasms 2 Mesothelioma, Malignant 2 Gastrointestinal Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma, Renal Cell 2 Carcinoma, Large Cell 2 Carcinoma, Hepatocellular 2 Brain Neoplasms 2 Adenocarcinoma 2 Vaccinia 1 Thoracic Neoplasms 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Sexual Dysfunction, Physiological 1 Respiratory Tract Neoplasms 1 Resectable Non-small Cell Lung Cancer 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1

Interventions

osimertinib 11 Pemetrexed 11 Carboplatin 11 aflutinib 8 Gefitinib 8 Drug Therapy 8 Radiotherapy 6 anlotinib 5 Docetaxel 5 Cisplatin 5 pembrolizumab 4 icotinib 4 Vinorelbine 4 Radiosurgery 4 Paclitaxel 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 rezivertinib 2 dacomitinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06865339 2025-09-10

TRIPL

Albert Einstein College of Medicine

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡